Full history for every metric is available with a Kvantra account
Bionomics Limited (BNO.AX)
Key financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD bn | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | AUD bn | -18 | -29 | |||||
| Net profit | AUD bn | -0 | -0 | -0 | -0 | -0 | -15 | - |
| EPS reported | AUD | -1,899 | - | |||||
| Operating cashflow per share | AUD | -1.80 | -1.80 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -1.80 | -1.80 | |||||
| Free cash flow | AUD bn | -0 | 0 | |||||
| Net debt | AUD bn | -0 | -0 | |||||
| Book value equity | AUD bn | 0 | 0 | |||||
| Book value per share | AUD | 2.14 | 3.89 | |||||
| Number of shares | m | 8.16 | 10.69 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.00 | 0.32 | |||||
| P/S LTM | x | 0.00 | 0.53 | |||||
| P/FCF LTM | x | -0.01 | 1.81 | |||||
| EV/EBITDA LTM | x | 1.25 | 1.75 | |||||
| EV/Sales LTM | x | 0.00 | -0.57 | |||||
| Earnings Yield LTM | % | -18986332.9% | -21095925.4% | |||||
| FCF Yield | % | -17991.9% | 55.24% | |||||
| Quality | ||||||||
| ROE | % | -88575.4% | -78305.9% | |||||
| ROIC | % | 559836.6% | 559836.6% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -53.83 | 32.34 | |||||
| Net Debt/EBITDA | x | 1.25 | 1.25 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -15411.2% | -206.42% | |||||
| Net debt/Equity | x | -0.72 | -0.66 | |||||
| Gross debt/equity | x | 0.02 | 0.01 | |||||
Company overview
Established in 1996 and headquartered in Eastwood, Australia, Bionomics Limited operates as a clinical-stage biopharmaceutical firm. The company's mission is to identify and advance innovative drug treatments, primarily focusing on central nervous system (CNS) conditions and various forms of cancer. Its key experimental therapeutic, BNC210, is a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor, currently undergoing Phase 2 trials for social anxiety disorder and more advanced Phase 2b trials for post-traumatic stress disorder (PTSD). Bionomics' pipeline also includes BNC101, a monoclonal antibody designed to specifically target cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Furthermore, BNC105 is advancing through Phase 2 trials for refractory colorectal cancer and Phase 1 trials for individuals with relapsed or refractory chronic lymphocytic leukemia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Bionomics Limited (BNO.AX)
Established in 1996 and headquartered in Eastwood, Australia, Bionomics Limited operates as a clinical-stage biopharmaceutical firm. The company's mission is to identify and advance innovative drug treatments, primarily focusing on central nervous system (CNS) conditions and various forms of cancer. Its key experimental therapeutic, BNC210, is a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor, currently undergoing Phase 2 trials for social anxiety disorder and more advanced Phase 2b trials for post-traumatic stress disorder (PTSD). Bionomics' pipeline also includes BNC101, a monoclonal antibody designed to specifically target cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Furthermore, BNC105 is advancing through Phase 2 trials for refractory colorectal cancer and Phase 1 trials for individuals with relapsed or refractory chronic lymphocytic leukemia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free